Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J‐mono trial
ABSTRACT Aims/Introduction In the SURPASS J‐mono trial, tirzepatide demonstrated significant improvements in bodyweight and several metabolic parameters in Japanese participants with type 2 diabetes. This post hoc analysis evaluated the potential relationships between weight loss and metabolic impro...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-05-01
|
| Series: | Journal of Diabetes Investigation |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jdi.14395 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850148147631751168 |
|---|---|
| author | Hanaka Mimura Tomonori Oura Rina Chin Masakazu Takeuchi Kazuya Fujihara Hirohito Sone |
| author_facet | Hanaka Mimura Tomonori Oura Rina Chin Masakazu Takeuchi Kazuya Fujihara Hirohito Sone |
| author_sort | Hanaka Mimura |
| collection | DOAJ |
| description | ABSTRACT Aims/Introduction In the SURPASS J‐mono trial, tirzepatide demonstrated significant improvements in bodyweight and several metabolic parameters in Japanese participants with type 2 diabetes. This post hoc analysis evaluated the potential relationships between weight loss and metabolic improvements in SURPASS J‐mono. Materials and Methods Metabolic parameter data from tirzepatide‐treated participants were analyzed by weight loss subgroups and compared to dulaglutide 0.75 mg. Correlations between changes from baseline to week 52 in weight loss and each metabolic parameter were assessed; Pearson correlation coefficients were derived. Mediation analyses were conducted to evaluate weight loss‐associated and ‐unassociated effects of tirzepatide vs dulaglutide 0.75 mg. Results This analysis included 548 participants (tirzepatide: n = 411, dulaglutide: n = 137). Weight loss subgroups showed greater improvement in metabolic parameters with greater bodyweight loss. Significant (P < 0.05) but weak correlations between changes in bodyweight and triglycerides (r = 0.18–0.25), high‐density lipoprotein cholesterol (r = −0.37 to −0.29), and systolic blood pressure (r = 0.19–0.41) were observed across treatment groups; in diastolic blood pressure in the tirzepatide 5‐mg (r = 0.28), pooled tirzepatide (r = 0.20), and dulaglutide 0.75‐mg (r = 0.23) groups; and in fasting serum glucose in the dulaglutide 0.75‐mg (r = 0.18) and pooled tirzepatide (r = 0.13) groups. Weight loss was associated with treatment differences between tirzepatide and dulaglutide 0.75 mg to varying degrees across metabolic parameters, with improvements in fasting serum glucose having the lowest association with weight loss (36.6%–43.5%). Conclusions In this post hoc analysis, non‐glycemic and glycemic parameter improvements appeared differentially associated with weight loss, suggesting both weight loss‐associated and ‐unassociated effects of tirzepatide. |
| format | Article |
| id | doaj-art-3a3c3a69be764dd6973f3afc1147bc0b |
| institution | OA Journals |
| issn | 2040-1116 2040-1124 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Investigation |
| spelling | doaj-art-3a3c3a69be764dd6973f3afc1147bc0b2025-08-20T02:27:19ZengWileyJournal of Diabetes Investigation2040-11162040-11242025-05-0116580781610.1111/jdi.14395Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J‐mono trialHanaka Mimura0Tomonori Oura1Rina Chin2Masakazu Takeuchi3Kazuya Fujihara4Hirohito Sone5Japan Drug Development and Medical Affairs Eli Lilly Japan K.K. Kobe JapanJapan Drug Development and Medical Affairs Eli Lilly Japan K.K. Kobe JapanJapan Drug Development and Medical Affairs Eli Lilly Japan K.K. Kobe JapanJapan Drug Development and Medical Affairs Eli Lilly Japan K.K. Kobe JapanDepartment of Hematology, Endocrinology and Metabolism Niigata University Faculty of Medicine Niigata JapanDepartment of Hematology, Endocrinology and Metabolism Niigata University Faculty of Medicine Niigata JapanABSTRACT Aims/Introduction In the SURPASS J‐mono trial, tirzepatide demonstrated significant improvements in bodyweight and several metabolic parameters in Japanese participants with type 2 diabetes. This post hoc analysis evaluated the potential relationships between weight loss and metabolic improvements in SURPASS J‐mono. Materials and Methods Metabolic parameter data from tirzepatide‐treated participants were analyzed by weight loss subgroups and compared to dulaglutide 0.75 mg. Correlations between changes from baseline to week 52 in weight loss and each metabolic parameter were assessed; Pearson correlation coefficients were derived. Mediation analyses were conducted to evaluate weight loss‐associated and ‐unassociated effects of tirzepatide vs dulaglutide 0.75 mg. Results This analysis included 548 participants (tirzepatide: n = 411, dulaglutide: n = 137). Weight loss subgroups showed greater improvement in metabolic parameters with greater bodyweight loss. Significant (P < 0.05) but weak correlations between changes in bodyweight and triglycerides (r = 0.18–0.25), high‐density lipoprotein cholesterol (r = −0.37 to −0.29), and systolic blood pressure (r = 0.19–0.41) were observed across treatment groups; in diastolic blood pressure in the tirzepatide 5‐mg (r = 0.28), pooled tirzepatide (r = 0.20), and dulaglutide 0.75‐mg (r = 0.23) groups; and in fasting serum glucose in the dulaglutide 0.75‐mg (r = 0.18) and pooled tirzepatide (r = 0.13) groups. Weight loss was associated with treatment differences between tirzepatide and dulaglutide 0.75 mg to varying degrees across metabolic parameters, with improvements in fasting serum glucose having the lowest association with weight loss (36.6%–43.5%). Conclusions In this post hoc analysis, non‐glycemic and glycemic parameter improvements appeared differentially associated with weight loss, suggesting both weight loss‐associated and ‐unassociated effects of tirzepatide.https://doi.org/10.1111/jdi.14395Bodyweight lossTirzepatideType 2 diabetes mellitus |
| spellingShingle | Hanaka Mimura Tomonori Oura Rina Chin Masakazu Takeuchi Kazuya Fujihara Hirohito Sone Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J‐mono trial Journal of Diabetes Investigation Bodyweight loss Tirzepatide Type 2 diabetes mellitus |
| title | Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J‐mono trial |
| title_full | Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J‐mono trial |
| title_fullStr | Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J‐mono trial |
| title_full_unstemmed | Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J‐mono trial |
| title_short | Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J‐mono trial |
| title_sort | association of bodyweight loss with changes in lipids blood pressure and fasting serum glucose following tirzepatide treatment in japanese participants with type 2 diabetes a post hoc analysis of the surpass j mono trial |
| topic | Bodyweight loss Tirzepatide Type 2 diabetes mellitus |
| url | https://doi.org/10.1111/jdi.14395 |
| work_keys_str_mv | AT hanakamimura associationofbodyweightlosswithchangesinlipidsbloodpressureandfastingserumglucosefollowingtirzepatidetreatmentinjapaneseparticipantswithtype2diabetesaposthocanalysisofthesurpassjmonotrial AT tomonorioura associationofbodyweightlosswithchangesinlipidsbloodpressureandfastingserumglucosefollowingtirzepatidetreatmentinjapaneseparticipantswithtype2diabetesaposthocanalysisofthesurpassjmonotrial AT rinachin associationofbodyweightlosswithchangesinlipidsbloodpressureandfastingserumglucosefollowingtirzepatidetreatmentinjapaneseparticipantswithtype2diabetesaposthocanalysisofthesurpassjmonotrial AT masakazutakeuchi associationofbodyweightlosswithchangesinlipidsbloodpressureandfastingserumglucosefollowingtirzepatidetreatmentinjapaneseparticipantswithtype2diabetesaposthocanalysisofthesurpassjmonotrial AT kazuyafujihara associationofbodyweightlosswithchangesinlipidsbloodpressureandfastingserumglucosefollowingtirzepatidetreatmentinjapaneseparticipantswithtype2diabetesaposthocanalysisofthesurpassjmonotrial AT hirohitosone associationofbodyweightlosswithchangesinlipidsbloodpressureandfastingserumglucosefollowingtirzepatidetreatmentinjapaneseparticipantswithtype2diabetesaposthocanalysisofthesurpassjmonotrial |